AstraZeneca PLC

Stable AstraZeneca PLC shares, a diversified therapeutic pipeline, and proactive regulatory strategy signal continued confidence and growth prospects for investors.

Read how AstraZeneca’s latest update shows a mix of oncology setbacks, a breakthrough therapy win for Enhertu, and a strategic exit from Andexxa, illustrating the company’s dynamic portfolio strategy and regulatory moves.

Read how AstraZeneca’s oncology mix—lung‑cancer setback vs. breast‑cancer breakthrough and safety‑driven product pull—shows its strategic resilience.

Discover why AstraZeneca’s ovarian‑cancer phase‑three study and strategic market‑access plan could boost its $26 billion revenue forecast and 12 % IRR—read the latest analyst insights and M&A prospects.

Imfinzi’s FDA approval for peri‑operative gastric cancer marks a breakthrough, pairing powerful immunotherapy with FLOT chemotherapy to cut progression risk by 28% and boosting AstraZeneca’s market and patient‑care impact.

Explore AstraZeneca’s NYSE direct listing and 2025 earnings forecast—EPS up 5.5%, liquidity strengths, and risks of patent expirations.

Read how AstraZeneca’s shareholder‑approved NYSE direct listing will boost capital for oncology and cardiovascular R&D, improve market visibility, and speed patient access to new therapies.

AstraZeneca PLC faces regulatory scrutiny over a breach of the UK’s pharmaceutical code of practice, but its strong financial outlook and favorable market sentiment remain intact, with analysts predicting continued growth and a premium valuation.

AstraZeneca has announced a landmark agreement with the US government to offer discounts of up to 80% off list prices for eligible patients, securing a large and stable revenue stream through Medicaid and positioning the company for future market ac…

AstraZeneca PLC has announced a strategic restructuring of its share-listing framework, moving its ordinary shares from a US ADR program to a direct listing on the NYSE while maintaining its primary London listing, with expected benefits including r…